| Study |
Reference |
|
Elsenity, 2022
|
Elsenity, M.A. Hydroxychloroquine therapy in women with autoimmune recurrent pregnancy loss, refractory to low dose aspirin and heparin: A randomized controlled trial Vopr. Ginekol. Akus. Perinatol. 2022; 21:19-.
|
|
Gerde, 2021
|
Gerde The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. Thromb Res 2021; 206:104-110
|
|
Latino, 2020
|
Aranda, F. The impact of hydroxychloroquine on the prevention of severe preeclampsia in patients with obstetric anti-phospholipid syndrome Res. Pract. Thromb. Haemost. 2020; 4:1293-. Latino Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine. Lupus 2020; 29:1736-1742
|
|
Lockshin, 2012
|
Lockshin Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012; 64:2311-8
|
|
Mekinian, 2015
|
Mekinian The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev 2015; 14:498-502
|
|
Mekinian, 2016
|
Mekinian Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies. Semin. Arthritis Rheum. 2016; 46:232-237
|
|
Ruffatti, 2018
|
Ruffatti Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thromb. Haemost. 2018; 118:639-646
|
|
Sciascia, 2016
|
Sciascia The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 2016; 214:273.e1-273.e8
|
|
Ye, 2017
|
Ye Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome-related Recurrent Spontaneous Abortion. Chin. Med. J. 2017; 130:1395-1399
|
|
Yelnik, 2016
|
Yelnik Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3:e000131
|
